CA3106115A1 - Antibody libraries with maximized antibody developability characteristics - Google Patents
Antibody libraries with maximized antibody developability characteristics Download PDFInfo
- Publication number
- CA3106115A1 CA3106115A1 CA3106115A CA3106115A CA3106115A1 CA 3106115 A1 CA3106115 A1 CA 3106115A1 CA 3106115 A CA3106115 A CA 3106115A CA 3106115 A CA3106115 A CA 3106115A CA 3106115 A1 CA3106115 A1 CA 3106115A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- light chain
- population
- heavy chain
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695065P | 2018-07-08 | 2018-07-08 | |
| US62/695,065 | 2018-07-08 | ||
| US201962822671P | 2019-03-22 | 2019-03-22 | |
| US62/822,671 | 2019-03-22 | ||
| PCT/US2019/040843 WO2020014143A1 (en) | 2018-07-08 | 2019-07-08 | Antibody libraries with maximized antibody developability characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3106115A1 true CA3106115A1 (en) | 2020-01-16 |
Family
ID=69102540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3106115A Pending CA3106115A1 (en) | 2018-07-08 | 2019-07-08 | Antibody libraries with maximized antibody developability characteristics |
Country Status (5)
| Country | Link |
|---|---|
| US (8) | US10954508B2 (https=) |
| EP (1) | EP3833685A4 (https=) |
| JP (2) | JP7332691B2 (https=) |
| CA (1) | CA3106115A1 (https=) |
| WO (1) | WO2020014143A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| US20230167165A1 (en) * | 2021-07-07 | 2023-06-01 | Specifica Inc. | Antibody affinity maturation using natural liability-free cdrs |
| CA3244280A1 (en) * | 2022-02-17 | 2023-08-24 | Rules-Based Medicine Inc. | SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS |
| WO2023232857A1 (en) * | 2022-06-03 | 2023-12-07 | Ichnos Sciences SA | Common light chain antibody libraries |
| IL320284A (en) * | 2022-10-18 | 2025-06-01 | Tubulis Gmbh | Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof |
| CN118496354A (zh) * | 2023-02-15 | 2024-08-16 | 三优生物医药(上海)有限公司 | 包含共同轻链的抗体库、其制备方法及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322614A1 (en) | 1995-06-07 | 2011-05-18 | Life Technologies Corporation | Recombinational cloning using engineered recombination sites |
| ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| US20060160178A1 (en) | 2003-11-17 | 2006-07-20 | Jonathan Rothberg | Methods of generating antibody diversity in vitro |
| JP2008504356A (ja) * | 2004-06-30 | 2008-02-14 | ドマンティス リミテッド | 炎症性疾患を治療するための組成物及び方法 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| PE20110385A1 (es) * | 2008-07-18 | 2011-06-22 | Bristol Myers Squibb Co | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| EP3246434A1 (en) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Method for preparing novel antibody library and library prepared thereby |
| EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY |
-
2019
- 2019-07-08 EP EP19834483.0A patent/EP3833685A4/en active Pending
- 2019-07-08 WO PCT/US2019/040843 patent/WO2020014143A1/en not_active Ceased
- 2019-07-08 JP JP2021523556A patent/JP7332691B2/ja active Active
- 2019-07-08 CA CA3106115A patent/CA3106115A1/en active Pending
- 2019-07-08 US US16/505,358 patent/US10954508B2/en active Active
-
2021
- 2021-01-29 US US17/163,170 patent/US11920258B2/en active Active
- 2021-03-22 US US17/208,877 patent/US11254931B2/en active Active
-
2023
- 2023-08-09 JP JP2023129892A patent/JP2023145778A/ja active Pending
-
2024
- 2024-02-01 US US18/430,601 patent/US20240384437A1/en active Pending
- 2024-02-29 US US18/592,499 patent/US12344959B2/en active Active
- 2024-02-29 US US18/592,484 patent/US12351946B2/en active Active
- 2024-02-29 US US18/592,473 patent/US12351945B2/en active Active
- 2024-02-29 US US18/592,456 patent/US12359346B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240384437A1 (en) | 2024-11-21 |
| US11920258B2 (en) | 2024-03-05 |
| WO2020014143A1 (en) | 2020-01-16 |
| US11254931B2 (en) | 2022-02-22 |
| US12351946B2 (en) | 2025-07-08 |
| US20210171936A1 (en) | 2021-06-10 |
| US12351945B2 (en) | 2025-07-08 |
| US12359346B2 (en) | 2025-07-15 |
| JP2021531822A (ja) | 2021-11-25 |
| US20240384439A1 (en) | 2024-11-21 |
| JP7332691B2 (ja) | 2023-08-23 |
| US20200010828A1 (en) | 2020-01-09 |
| JP2023145778A (ja) | 2023-10-11 |
| EP3833685A1 (en) | 2021-06-16 |
| US12344959B2 (en) | 2025-07-01 |
| US20240240360A1 (en) | 2024-07-18 |
| US20240384440A1 (en) | 2024-11-21 |
| US20240229297A1 (en) | 2024-07-11 |
| US20210214720A1 (en) | 2021-07-15 |
| EP3833685A4 (en) | 2022-08-17 |
| US10954508B2 (en) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12344959B2 (en) | Antibody libraries with maximized antibody developability characteristics | |
| CN102449149B (zh) | 集合及其使用方法 | |
| EP2640742B1 (en) | A collection of antibody sequences its use | |
| JP2011511647A (ja) | 特異的結合対を作製するための改善された方法 | |
| US12258679B2 (en) | Polyclonal mixtures of antibodies, and methods of making and using them | |
| US12442107B2 (en) | Single domain antibody libraries with maximized antibody developability characteristics | |
| KR102194203B1 (ko) | 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들) | |
| US20230295271A1 (en) | Methods and compositions for in vitro affinity maturation of monoclonal antibodies | |
| KR20220026869A (ko) | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 | |
| HK1187626A (en) | A collection and methods for its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20241010 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250213 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250708 |